United Freedom-C(2) Phase 3 trial fails to meet primary endpoint
In the study, the patients were optimized on an endothelin receptor antagonist, a phosphodiesterase-5 inhibitor, or both. The trial involved around 310 patients. United Therapeutics’ president and chief
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.